MedTrace Logo

ReNu™ Marrow Stimulation Augmentation

NCT03036878 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2020-01-18

No results posted yet for this study

Summary

To evaluate the use of ReNu™ allograft for the augmentation of marrow stimulation for osteochondral lesions

Conditions

  • Osteochondral Defect

Interventions

OTHER

ReNu

ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.

Sponsors & Collaborators

  • Organogenesis

    collaborator INDUSTRY

  • NuTech Medical, Inc

    lead INDUSTRY

Principal Investigators

  • Jack Farr, MD · OrthoIndy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-07
Primary Completion
2019-12-06
Completion
2019-12-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03036878 on ClinicalTrials.gov